Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Breast Neoplasms 1

Interventions

Rituximab 9 Cyclophosphamide 9 ibrutinib 7 fludarabine phosphate 7 Peripheral Blood Stem Cell Transplantation 7 Whole-Body Irradiation 4 Radiotherapy 4 Filgrastim 4 Cytarabine 4 Bendamustine Hydrochloride 4 fludarabine 3 Vincristine 3 Prednisone 3 Mycophenolic Acid 3 Melphalan 3 Lenalidomide 3 Etoposide 3 Doxorubicin 3 Carmustine 3 Tacrolimus 2 Pentostatin 2 Pentetic Acid 2 Methotrexate 2 Magnetic Resonance Spectroscopy 2 Dexamethasone 2 Cyclosporine 2 Cord Blood Stem Cell Transplantation 2 CT-P10 2 Bortezomib 2 venetoclax 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphoma, Mantle-Cell × parsaclisib × Clear all

NCT04849715 2022-04-29

CITADEL-310

Incyte Corporation

Phase 3 Withdrawn

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡